Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yigan Xiaoji Formula (YGXJ) is a Traditional Chinese Medicine (TCM) herbal formula developed for the treatment of liver cirrhosis and hepatic fibrosis. It is primarily researched by investigators at Dongzhimen Hospital, Beijing University of Chinese Medicine. In preclinical models of early liver cirrhosis, YGXJ has been shown to improve liver function (reducing ALT and AST levels), inhibit hepatocyte degeneration, reduce collagen fiber deposition, and suppress hepatic stellate cell activation. Its mechanism of action involves modulating the balance of Ly6C<sup>hi</sup>/Ly6C<sup>lo</sup> macrophages, down-regulating the expression of pro-inflammatory cytokines such as TNF-alpha and IL-1beta, and up-regulating matrix metalloproteinases MMP9 and MMP12 to prevent disease progression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yigan Xiaoji Formula.